ABSTRACT OBJECTIVE: Non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS) is one of the rare causes of endogenous hyperinsulinism. Its diagnosis is challenging and may require selective intraarterial calcium stimulation and concomitant hepatic vein sampling (SACVS). Impaired counterregulatory hormones' production in response to hypoglycemia has been previously described in patients with diabetes, insulinoma and infancy hypoglycemia. We present a case of endogenous hyperinsulinism, secondary to NIPHS, with deficient cortisol response to hypoglycemia which resolved after diazoxide treatment. DESIGN-RESULTS: A 43-year-old woman was admitted with recurrent episodes of registered fasting and postprandial hypoglycemia. Abdominal computed tomography, magnetic resonance imaging and endoscopic ultrasonography of the pancreas failed to reveal any lesion while SACVS sampling demonstrated a 5-to 8-fold increase in insulin levels in diverse parts of the pancreas. Counterregulatory hormones' measurement revealed an attenuated cortisol response. Treatment with diazoxide resulted in disappearance of hypoglycemic episodes. Twelve months later, an insulin tolerance test was performed which revealed a normal cortisol response. CONCLUSIONS: This report describes the first, to our knowledge, reported case in the literature of NIPHS with deficient cortisol response to hypoglycemia which resolved after diazoxide treatment. It is important for clinicians to include NIPHS in the differential diagnosis of hypoglycemia and identify possible impairment of counterregulatory hormones' production.
INTRODUCTION
Endogenous hyperinsulinism (EH) comprises a group of rare causes of hypoglycemia including insulinomas, non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS), autoimmune hypoglycemia and focal or diffuse islet cell hyperplasia in infants (congenital hyperinsulinism). Insulinomas are the most common cause of EH with an estimated incidence of 1 to 4 new cases per million patient-years.
1,2 Rarely, they can be malignant or they can be encountered as part of MEN-1 syndrome or, even rarer, of neurofibromatosis type 1 and tuberous sclerosis. 1, [3] [4] [5] In 0.5-5% of patients, insulin excretion is derived from NIPHS. 6, 7 Patients with insulinomas are usually characterized by symptoms and signs related to fasting hypoglycemia and disproportionally high insulin levels in the presence of hypoglycemia. In the absence of typical registered hypoglycemic episodes, a prolonged supervised 72h fast is required. Frequently, insulinoma localization can be difficult and challenging due to their small size. 8 Referral to specialized centers for endoscopic ultrasound and selective arterial calcium stimulation with hepatic vein sampling (SACVS) may be required. In most of the cases, surgical removal of the encapsulated tumor or part of the pancreas can be curative.
On the other hand, NIPHS is characterized by endogenous hyperinsulinemic hypoglycemia that is not caused by an insulinoma. The diagnosis should be suspected in patients with predominant postprandial hyperinsulinemic hypoglycemia, negative radiological localizing studies, and positive responses to SACVS in diverse parts of the pancreas. he etiology of NIPHS remains unknown, while the histological exam shows beta-cell hypertrophy. The majority of cases are related to preceding bariatric surgery, suggesting a reactive process possibly due to glucagon-like peptide 1 (GLP-1)-induced islet cell proliferation and hyperplasia. 9 Gene mutations encoding subunits (Kir6.2 and SUR1) of the pancreatic ATP-sensitive potassium (K-ATP) channel, which are encountered in cases of congenital hyperinsulinism, are lacking in NIPHS. 9, 10 Amelioration of symptoms occurs with partial or subtotal pancreatectomy, or with medical treatment with diazoxide or somatostatin analogues to block insulin release.
Regardless of the cause of hypoglycemia, counterregulatory hormones such as glucagon, adrenaline, noradrenaline, growth (GH), adrenocorticotropic hormone (ACTH) and cortisol are produced in increased amounts during a hypoglycemic episode in order to restore normal glucose levels. Normally, glucagon and epinephrine are secreted at the glycemic threshold level of approximately 3.8 mmol/L (68 mg/ dL), GH secretion occurs at 3.7 mmol/L (66 mg/dL) and secretion of cortisol at 3.2 mmol/L (58 mg/dL).
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Recurrent and/or persistent episodes of hypoglycemia can lower the threshold of counterregulatory hormone production. Defects in counterregulatory hormone secretion can be present in patients with diabetes mellitus (DM), congenital hyperinsulinism and insulinoma who may present with attenuated adrenaline, and/or noradrenaline, GH and cortisol responses to hypoglycemia. [12] [13] [14] [15] [16] Tumor enucleation or partial/subtotal pancreatectomy successfully relieves hypoglycemic symptoms and restores counterregulatory hormonal response in the majority of patients with insulinoma or NIPHS. However, restoration of defective hormonal response with pharmaceutical treatment in NIPHS patients has not been previously described.
In this article we report a case of NIPHS with defective cortisol response to hypoglycemia which resolved following medical treatment with diazoxide. We provide a brief overview of the existing literature, suggest potential underlying mechanisms for this complication and discuss therapeutic options and their possible mechanism of action.
CASE REPORT
A 43-year-old woman (BMI: 25.4) was admitted complaining of light-headedness, chills, lack of concentration, nervousness, muscle weakness and three recent episodes of losing consciousness followed by very low plasma glucose levels [Glu: 1.10-1.21 mmol/L (20-22 mg/dl), HbA1c: 3.7%]. Prior liver, renal, anterior pituitary and adrenal function were normal, while hormonal investigation with a supervised fast documented endogenous hyperinsulinism. Radiologic evaluation with abdominal computed tomography (CT) and magnetic resonance imaging (MRI) failed to detect an insulinoma. Treatment with diazoxide 50 mg per day had already been initiated; nevertheless, the patient did not comply with taking diazoxide, and had no proper medical follow-up. Medical and family history was unremarkable.
During her stay in our department, hypoglycemia [Glu <2.48 mmol/L (45 mg/dl)] was documented over four consecutive days following a 12-hour overnight fast. The patient had total lack of adrenergic symptoms. Other causes of hypoglycemia were excluded. Hypoglycemia was followed by inappropriately high plasma insulin (Table 1 ) and C-peptide levels (2.3 nmol/L) indicative of endogenous hyperinsulinism. After glucagon administration, glucose levels were increased by only 1.37 mmol/L (25 mg/dl) despite profound hyperinsulinemia [plasma insulin: 473.65 pmol/L (68.2 IU/ml)] indicating an almost complete depletion of hepatic glycogen stores.
Cortisol and GH measurement revealed inappropriately low plasma cortisol levels [maximum: 185 nmol/L (6.7 g/dl)], appropriately increased GH levels, while ACTH, renin and aldosterone levels were normal, practically excluding the diagnosis of primary adrenal insufficiency. ACTH stimulation (Synacthen 250 g) and corticotropin-releasing hormone stimulation (CRH) tests were performed in order to differentiate between potential secondary and tertiary adrenal insufficiency. Cortisol response was normal in both tests with a maximum of 940 nmol/L (34 g/ dl) at 60 min in the Synachten test and 726 nmol/L (26.28 g/dl) at 45 min in the CRH test. An insulin tolerance test (ITT) to evaluate cortisol response was not performed as the patient had very low morning basal cortisol levels and complete unawareness of hypoglycemia. Due to the fact that the patient had also reported postprandial neuroglycopenia, a prolonged 3-hour 75-gr oral glucose tolerance test (OGTT) was performed. Profound hyperinsulinemia was detected after 30 minutes [glucose: 5.55 (100 mg/dl) and insulin: >1736.2 pmol/L (250 IU/ml)], whereas asymptomatic hypoglycemia with concomitant hyperinsulinemia [Glu: 2.31 mmol/L (42 mg/dl) and insulin: 430.6 pmol/L (62 IU/ml)] after 150 minutes.
Pancreas-focused abdominal CT and MRI, as well as endoscopic pancreatic ultrasonography (EUS) and 111 I-octreotide scintigraphy were normal. Subsequent SACVS failed to regionalize a positive response in a single specific region, thus allowing a therapeutic partial pancreatectomy, since there was a positive response in all main arteries that perfuse the pancreas. 17 The SACVS procedure and the interpretation of the results in the localization of EH are depicted in Figure 1 .
Clinical data, hormonal and biochemical findings, stimulatory tests and localization studies led, by exclusion, to the diagnosis of NIPHS. Medical treatment with diazoxide (100 mg twice daily) was initiated with excellent results. ]. An ITT was also performed in order to validate the adrenal response and to identify if there was an increase in the glycemic threshold for cortisol hormone secretion. Cortisol and ACTH response to ITT was adequate. Nonetheless, response to ACTH, which was carried out in order to achieve restoration of normal glucose levels, was exaggerated and delayed (Table 2a) . After six more months, an ITT was performed again and this time it revealed normal cortisol and ACTH response to hypoglycemia in the face of normal basal morning cortisol levels (Table  2b) . ACTH and CRH stimulation tests also showed adequate cortisol response. Glucose, insulin, cortisol and GH levels before diazoxide treatment and 6 and 12 months following diazoxide treatment are shown in Table 1 .
DISCUSSION
Recognition and diagnosis of rare EH causes can be challenging. We describe a case of hyperinsulinism secondary to NIPHS with impairment of cortisol response to recurrent episodes of hypoglycemia, which resolved after diazoxide treatment, and highlight the role of K-ATP channels in insulin secretion and hypoglycemia counterregulation.
NIPHS diagnosis often requires laborious biochemical and imaging investigation and can rarely be made before surgery. 7 Differential diagnosis from insulinoma is important in order to evaluate the option of a possible surgical resection and can be accomplished through SACVS. In our patient, NIPHS was a diagnosis by exclusion based on biochemical findings of fasting and postprandial hyperinsulinemic hypoglycemia and positive SACVS test in diverse parts of the pancreas. Apart from the conventional arteries, further catheterization of the distal part of the splenic artery was performed in order to acquire more data on possible insulin secretion from the pancreatic body versus tail, while magna pancreatic artery was additionally catheterized as there were anatomic variations regarding other patients' arteries (renal). In our case, ACTH levels and serum cortisol response were inappropriately low for the degree and severity of hypoglycemia, suggesting an impairment of the hypothalamic-pituitary axis. On the other hand, ACTH and CRH administration induced an adequate increase in cortisol levels confirming a centrally mediated phenomenon. ACTH response to hypoglycemia was greater in the ITT performed at 6 months following diazoxide initiation compared to that performed at 12 Figure 1 . Insulin levels from diverse pancreatic arteries during selective arterial calcium stimulation and hepatic venous sampling (SACVS). Calcium injection into the distal part of the SpA localized increased insulin secretion to the pancreatic tail whereas calcium administration to the proximal part of SpA was indicative of increased insulin secretion in the pancreatic body. In addition, selective calcium injection into GDA, MPA and DSA which respectively supply the pancreatic head, body and tail, revealed increased insulin secretion from all the aforementioned parts of the pancreas. SACVS procedure: A catheter was placed in the right hepatic vein via femoral venous puncture. After catheterization of the femoral artery, standard pancreatic angiography was performed including selective injections of contrast agent into the gastroduodenal (GDA), proximal splenic (SpA) and superior mesenteric (SMA) artery. Following each angiogram, calcium gluconate (0.025 mEq Ca ++ /kg body weight) was injected into each selectively catheterized artery. In addition to the standard SACVS procedure, calcium was injected superselectively into the distal part of the SpA and into the magna pancreatic artery. The time period between each calcium injection was at least 5 minutes. Blood samples were drawn from the right hepatic vein before and 30, 60, 90 and 120 seconds after each calcium injection. A greater than 2-fold rise in insulin levels within 30-120 seconds after the injection of calcium was required to localize abnormal insulin secretion in the portion of the pancreas supplied by the artery studied. GDA: Gastroduodenal artery; SpA: Proximal splenic artery; MPA: Magna pancreatic artery; DSA: Distal part of splenic artery; SMA: Superior mesenteric artery.
VMH may modulate the magnitude of counterregulatory responses to hypoglycemia by altering release of gamma-amino-butyric acid (GABA) within that region. Normally, local delivery of glucose into VMH can dose-dependently suppress glucagon and epinephrine responses to hypoglycemia through stimulation of GABA release, whereas decrease in glucose concentration may enhance the counterregulatory responses to hypoglycemia through suppression of GABA release. 34 However, in recurrently hypoglycemic rats, closing of K-ATP channels in the VMH increases GABA levels thus suppressing counterregulatory responses to hypoglycemia. 35 On the other hand, opening of K-ATP channels decreases GABA output, and this in turn corresponds to amplification of counterregulatory responses. 36 Diazoxide reversibly inhibits glucose induced release of insulin in pancreatic beta cells by opening K-ATP sensitive channels and is used in cases of insulinoma, Dumping's syndrome and congenital hyperinsulinism. 37 Apart from a peripheral impact on -cells, diazoxide could have a central effect in the VMH. 37 It has been shown that K-ATP channels in VMH respond to diazoxide administration. 38 In animal models, diazoxide caused a twofold decrease in GABA levels and increased glucagon and epinephrine responses during hypoglycemia. 36 Our patient responded to diazoxide treatment not only with an elimination of hypoglycemic episodes but also with restoration of hypoglycemia awareness and of ACTH and cortisol response. Even though cathecholamine levels were not measured, recovery of adrenergic symptoms in the sole two hypoglycemic episodes that our patient had after diazoxide initiation, indicated a restoration of previously blunted adrenergic response. Diazoxide was preferred as a therapeutic option over SMS analogues due to its significantly lower cost, convenient route of administration and its potential beneficial effects on the VMH regarding glucose unawareness and restoration of counterregulatory hormones' response.
Apart from the pivotal role of GABA on defective counterregulatory hormonal response to hypoglycemia, other substances including insulin, lactate, endogenous opioids as well as peripheral glucose sensing neurons are also implicated. [39] [40] [41] [42] [43] [44] months, in the face of lower fasting glucose levels (3.36 vs 5.39 mmol/L). Furthermore, predominance of neuroglycopenic symptoms and lack of adrenergic ones also indicated an abnormal adrenaline response to hypoglycemia.
Counterregulatory hormones have a pivotal role in the restoration of normal serum glucose levels after hypoglycemia. Defects in counterregulation include decreased peak of hormonal (glucagon, cortisol, adrenaline) response to a hypoglycemic stimulus, abnormally decreased glycemic threshold for counterregulatory hormone release as well as hypoglycemia unawareness due to reduced sympathoadrenal responses. [18] [19] [20] [21] [22] In patients with insulinoma, apart from reduced glucagon levels there is also a defect in GH and ACTH release in response to hypoglycemia which could be related to hyperinsulinemia-induced reduction in GHRH pulse and CRF secretion. 23 Peak levels of epinephrine, norepinephrine and cortisol as well as glycemic threshold for counterregulatory hormones' secretion were increased after insulinoma removal, suggesting that the defective hormonal response may be at least partially reversible. 16 In addition, neonates with congenital hyperinsulinism have blunted serum cortisol response to hypoglycemia, whereas serum GH levels may have an appropriate response. 15, 24, 25 K-ATP channels play a key role in glucosensing. Both, increased intracellular glucose levels of -cells and use of sulfonylureas, inhibit efflux of potassium through the K-ATP channels, depolarizing the -cell membrane. This opens voltage-gated calcium channels facilitating calcium influx and a rise in its intracellular levels. As a result, insulin granules fuse with the cell membrane and proinsulin is secreted. 26 Components of the -pancreatic islet glucose-sensing machinery, including K-ATP channels, have also been identified in neurons of brain glucose-sensing regions, in the hypothalamus [lateral hypothalamic area and ventromedial hypothalamus (VMH)] and areas within the hindbrain and brainstem. [27] [28] [29] [30] [31] [32] [33] The exact mechanism by which low blood glucose exerts its central effects regarding defective counterregulatory hormone secretion and hypoglycemia unawareness is not known. Research focuses largely on VMH that serves as a satiety center. [29] [30] [31] Experiments in rats have shown that K-ATP channels within the In conclusion, this is the first report describing a case of NIPHS with deficient cortisol response to hypoglycemia which resolved after diazoxide treatment. Recognition, differential diagnosis and appropriate treatment of NIPHS are challenging. Mechanisms mediating defective hypoglycemia counterregulation are complex. Current research focuses on neurotransmitter signaling in diverse parts of the brain, mainly the hypothalamus. Pharmaceutical compounds, like diazoxide, that interfere with hypothalamic glucose awareness, might comprise a promising treatment option in cases of recurrent hyperinsulinemic hypoglycemia counterregulation defects.
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